Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (COCP) has dosed the last subject in its Phase 1b randomized, double-blind, placebo-controlled human challenge study evaluating oral antiviral candidate CDI-988 for both prevention and treatment of norovirus infection.
The study at Emory University School of Medicine enrolls healthy adults aged 18–49 who are infected with the norovirus GII.2 (Snow Mountain Virus) strain and receive CDI-988 or placebo. The primary endpoint is efficacy versus placebo in reducing the incidence of clinical symptoms, with secondary endpoints including reductions in viral shedding and disease severity, and assessment of safety and pharmacokinetics. No serious adverse events have been reported to date. CDI-988 previously completed a Phase 1 trial in Australia, where it was safe and well tolerated across all doses up to 1200 mg, the dose now used in the Phase 1b study. Preliminary efficacy results are expected in late 2026 or early 2027.
Cocrystal Pharma (Nasdaq: COCP) appointed Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. She brings decades of experience in antiviral therapy, epidemiology and biopharma advisory, including roles in developing FDA‑approved antiviral drugs Viread and Hepsera at Gilead Sciences.
According to Cocrystal, Dr. Brosgart’s clinical and scientific expertise is expected to support advancement of CDI-988 for norovirus and the company’s broader antiviral pipeline. She currently serves on multiple biotech boards and is a Clinical Professor of Medicine, Biostatistics and Epidemiology at UCSF.
Cocrystal Pharma (Nasdaq: COCP) entered into a $5 million private placement with longtime investor OPKO Health (Nasdaq: OPK). Cocrystal sold 5,474,053 common shares to OPKO at $0.9134 per share, equal to the Nasdaq Consolidated Bid Price on the closing day, with no warrants or other derivatives issued.
According to Cocrystal, the proceeds support advancement of its lead norovirus candidate CDI-988, with topline Phase 1b data expected by the end of the fourth quarter of 2026. Both companies highlighted OPKO’s longstanding support and confidence in Cocrystal’s antiviral pipeline.
Cocrystal Pharma (Nasdaq: COCP) appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board. The company is a clinical-stage biotech focused on novel antiviral therapeutics.
Sam Lee and Jim Martin step down as Co-CEOs; Lee becomes President and future Chief Scientific Officer, while Martin remains Chief Financial Officer. Sapirstein brings extensive antiviral development experience, participation in or leadership of 23 product launches, and a background as CEO or senior executive at several biopharma companies.
Cocrystal Pharma (Nasdaq: COCP) reported discovery-stage pan-viral replication inhibitors targeting hantavirus, bunyavirus and influenza. These direct-acting antivirals target a conserved region of the viral L-protein replication enzyme. In vitro data show potency with IC50 <50 nM against hantaan virus, related to Andes hantavirus. The company also highlighted its pan-viral protease inhibitor CDI-988, now in a Phase 1b norovirus challenge study, and plans to advance a pan-viral lead molecule to address viral diseases that currently lack approved antivirals or vaccines.
Cocrystal Pharma (Nasdaq: COCP) reported first quarter 2026 revenue of $225,000, all from an NIH SBIR award, versus no revenue in 2025. Net loss was $2.3 million ($0.17/share), similar to 2025. Unrestricted cash was $4.7 million with working capital of $3.7 million.
The company advanced CDI-988 for norovirus, completing enrollment in the first Phase 1b human challenge cohort and enrolling prevention/treatment cohorts, and obtained FDA Fast Track. It also progressed its influenza programs, including CC-42344 and an influenza A/B polymerase initiative supported by NIH funding.
Cocrystal Pharma (Nasdaq: COCP) presented klinical and preclinical data for CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, at ICAR 2026. Key disclosures: Phase 1 safety data, ongoing Phase 1b human challenge study with stage 1 fully enrolled, and FDA Fast Track designation.
Phase 1 found CDI-988 generally safe to 1,200 mg; Phase 1b uses 1,200 mg twice daily for five days to assess prevention and treatment endpoints including symptom incidence and viral shedding.
Cocrystal Pharma (Nasdaq: COCP) announced that the U.S. FDA granted Fast Track designation to CDI-988, an oral direct-acting protease inhibitor being developed to prevent and treat norovirus infection. The designation enables earlier FDA interactions, rolling NDA review, and potential Priority Review.
CDI-988 targets a conserved 3CL protease region; a Phase 1b norovirus challenge study is currently underway at Emory University to evaluate both prevention and treatment.
Cocrystal Pharma (Nasdaq: COCP) reported 2025 results and pipeline updates on March 31, 2026. The company began a Phase 1b norovirus human challenge study at Emory for oral protease inhibitor CDI-988.
Key 2025 financials: R&D $5.1M (vs $12.5M), G&A $4.0M (vs $5.3M), net loss $8.8M ($0.78/share, vs $17.5M), cash $7.7M (vs $9.9M), working capital $5.9M, and 11.3M shares outstanding.
Cocrystal Pharma (Nasdaq: COCP) announced first subjects dosed in a Phase 1b randomized, double-blind, placebo-controlled human challenge study evaluating oral antiviral CDI-988 for prevention and treatment of norovirus. The study at Emory will enroll up to 40 healthy adults aged 18–49 infected with GII.2 (Snow Mountain Virus).
Primary endpoint: reduction in clinical symptom incidence versus placebo. Secondary endpoints: viral shedding, disease severity, safety, and pharmacokinetics. CDI-988 previously showed favorable Phase 1 safety; FDA issued a Study May Proceed letter in Sept 2025 and Emory IRB approved the study in Dec 2025. No approved norovirus treatments exist; norovirus causes an estimated $60 billion annual global economic burden.